Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia

被引:98
作者
Sawyers, CL [1 ]
机构
[1] Univ Calif Los Angeles, Dept Med, Inst Mol Biol, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Dept Mol Pharmacol, Inst Mol Biol, David Geffen Sch Med, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, Dept Urol, Inst Mol Biol, David Geffen Sch Med, Los Angeles, CA 90095 USA
关键词
D O I
10.1016/S1535-6108(02)00080-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Activating mutations in the FLT3 receptor tyrosine kinase occur in 30% of patients with acute myeloid leukemia. Small molecule FLT3 kinase inhibitors show selective antitumor activity in preclinical models. Clinical studies are underway.
引用
收藏
页码:413 / 415
页数:3
相关论文
共 26 条
[1]   High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance [J].
Branford, S ;
Rudzki, Z ;
Walsh, S ;
Grigg, A ;
Arthur, C ;
Taylor, K ;
Herrmann, R ;
Lynch, KP ;
Hughes, TP .
BLOOD, 2002, 99 (09) :3472-3475
[2]   INDUCTION OF CHRONIC MYELOGENOUS LEUKEMIA IN MICE BY THE P210BCR/ABL GENE OF THE PHILADELPHIA-CHROMOSOME [J].
DALEY, GQ ;
VANETTEN, RA ;
BALTIMORE, D .
SCIENCE, 1990, 247 (4944) :824-830
[3]   Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].
Druker, BJ ;
Sawyers, CL ;
Kantarjian, H ;
Resta, DJ ;
Reese, SF ;
Ford, JM ;
Capdeville, R ;
Talpaz, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042
[4]   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Druker, BJ ;
Talpaz, M ;
Resta, DJ ;
Peng, B ;
Buchdunger, E ;
Ford, JM ;
Lydon, NB ;
Kantarjian, H ;
Capdeville, R ;
Ohno-Jones, S ;
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037
[5]   Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent [J].
Fabbro, D ;
Buchdunger, E ;
Wood, J ;
Mestan, J ;
Hofmann, F ;
Ferrari, S ;
Mett, H ;
O'Reilly, T ;
Meyer, T .
PHARMACOLOGY & THERAPEUTICS, 1999, 82 (2-3) :293-301
[6]  
Fong TAT, 1999, CANCER RES, V59, P99
[7]  
George DJ, 1999, CANCER RES, V59, P2395
[8]   Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].
Gorre, ME ;
Mohammed, M ;
Ellwood, K ;
Hsu, N ;
Paquette, R ;
Rao, PN ;
Sawyers, CL .
SCIENCE, 2001, 293 (5531) :876-880
[9]   Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines [J].
Hayakawa, F ;
Towatari, M ;
Kiyoi, H ;
Tanimoto, M ;
Kitamura, T ;
Saito, H ;
Naoe, T .
ONCOGENE, 2000, 19 (05) :624-631
[10]   The conformational plasticity of protein kinases [J].
Huse, M ;
Kuriyan, J .
CELL, 2002, 109 (03) :275-282